Johnson & Johnson’s Ketamine-Based Drug Treats Depression SO THEY SAY – July 22, 2024 - Close to 30 percent of the estimated 280 million people in the world living with major depressive disorder have treatment resistant depression. Sales of Spravato soared 60% to $27... Read More...Addiction RecoveryBig PharmaBooks, Memoirs, Films, and MediadepressionJuly 30 2024